Collegium Pharma (COLL) Appoints Vikram Karnani as CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Collegium Pharmaceutical (COLL) PT Lowered to $40 at Jefferies
November 11, 2024 3:55 PM ESTJefferies analyst Glen Santangelo lowered the price target on Collegium Pharmaceutical (NASDAQ: COLL) to $40.00 (from $44.00) while maintaining a Buy rating.
The analyst comments "Model update post 3Q results. Overall, we remain encouraged by momentum in the underlying pain portfolio, coupled with new LT... More
